AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Ernexa Therapeutics Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S74KP5
2.07▼ 0.01 (-0.48%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
2.08
Day's Range
2.03 – 2.09
52-Week Range
0.13 – 15.88
Volume
5,674
Avg Volume
48.7K
Share Statistics
Shares Outstanding
Employees
5
Exchange
XNAS
Listed
2021-03-26
Share count as of August 6, 2026

Ernexa Therapeutics Inc. Common Stock (ERNA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Ernexa Therapeutics Inc. Common Stock (ERNA)
What is Ernexa Therapeutics Inc. Common Stock's Market Cap?
Ernexa Therapeutics Inc. Common Stock's Market Cap is $3.4M, based on as-reported figures from SEC (XBRL) filings.
What is Ernexa Therapeutics Inc. Common Stock's Revenue (TTM)?
Ernexa Therapeutics Inc. Common Stock's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Ernexa Therapeutics Inc. Common Stock's Net Income (TTM)?
Ernexa Therapeutics Inc. Common Stock's Net Income (TTM) is -$12.3M, based on as-reported figures from SEC (XBRL) filings.
What is Ernexa Therapeutics Inc. Common Stock's EBITDA?
Ernexa Therapeutics Inc. Common Stock's EBITDA is -$13.7M, based on as-reported figures from SEC (XBRL) filings.
What is Ernexa Therapeutics Inc. Common Stock's Diluted EPS (TTM)?
Ernexa Therapeutics Inc. Common Stock's Diluted EPS (TTM) is -7.52, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ERNAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
Loss from operations
Other income (expense), net:
Forward sales contract expense—
Change in fair value of warrant liabilities—
Interest Expense
Non-Operating Income (Expense)
Total other income (expense), net
Loss before income taxes
Benefit (provision) for income taxes—
Net loss
Series A preferred stock dividend
Net loss attributable to common stockholders
Earnings Per Share (Basic)
Earnings Per Share (Diluted)